Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TA-65MD is a dietary supplement and medical food formulation containing a proprietary small molecule telomerase activator originally isolated from traditional Chinese medicine extracts, most notably from *Astragalus membranaceus*. It is designed to **activate telomerase**, the enzyme that maintains and elongates telomeres—the protective caps at the ends of chromosomes implicated in cellular aging. Clinical studies have investigated TA-65MD in various populations, particularly older adults and those with cardiovascular disease, showing it may increase telomere length, support immune cell counts, and reduce laboratory markers of inflammation. The mechanism of action, while not fully elucidated, centers on **activation of telomerase** in immune cells, potentially leading to healthier cellular aging and improved adaptive immunity[1][2][3][4][5][6][7]. TA-65MD is sold as a dietary supplement, is manufactured to cGMP standards, and has a generally recognized as safe (GRAS) designation. Most data come from phase II studies for cardiovascular disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TA-65MD.